latest update:
[TrialBase DB]

trial summary · NCT07490067

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

Personalizing Heart Failure Treatment With Genomics: A Clinical Trial to Understand the Mechanisms and Validate a Polygenic Risk Score for Beta-Blocker Response

Trial record from the TrialBase DB dataset, status RECRUITING, condition Heart Failure With Reduced Ejection Fraction, sponsored by University of Michigan. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07490067phase PHASE4enrollment 100start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.

Source record: https://clinicaltrials.gov/study/NCT07490067

Facts

registry idNCT07490067
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE4
study typeINTERVENTIONAL
lead conditionHeart Failure With Reduced Ejection Fraction
sponsorUniversity of Michigan
sponsor classOTHER
enrollment100
start date2026-12
primary completion2029-07
completion2029-07
results postednot reported

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

  • Metoprolol Succinate
  • Beta-Blocker Polygenic Score
  • Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)

Countries

  • United States

Intervention types: DEVICE, DRUG

Work with this record